Pfizer to pursue bringing Covid-19 vaccine to India after import relaxation

New Delhi: Pfizer Inc said on Tuesday it would work towards bringing the Covid-19 vaccine it developed with Germany‘s BioNTech to India after the government eased import rules, after withdrawing its application in February.

“We have noted the recent announcement with regard to the regulatory pathway for global vaccines,” a Pfizer spokesperson told Reuters in an email.

“We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government’s immunisation program.”

  • Related Posts

    CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

    The Central Drugs Standard Control Organisation (CDSCO) found one spurious and 220 not of standard quality (NSQ) drug samples from a batch tested randomly as part of the August drug…

    FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

    The action follows the department’s investigation into a large-scale unlicenced drug repacking and relabelling racket uncovered at a farmhouse in Bengaluru South district’s Bidadi on August 18. The Karnataka Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

    CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

    FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

    FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman